The DOI matches its Crossref record; 56 of the 56 references it cites were found in a registry or an index.
Vedolizumab treatment for immune checkpoint inhibitor-induced enterocolitis
Open accessAbstract
Immune checkpoint inhibitors (ICPI), such as ipilimumab [anti-cytotoxic T-lymphocyte antigen-4 (CTLA-4) antibody] and nivolumab or pembrolizumab [anti-programmed cell death protein-1 (PD-1) antibodies], improve survival in several cancer types. Since inhibition of CTLA-4 or PD-1 leads to non-selective activation of the immune system, immune-related adverse events (irAEs) are frequent. Enterocolitis is a common irAE, currently managed with corticosteroids and, if necessary, anti-tumor necrosis factor-α therapy. Such a regimen carries a risk of serious side-effects including infections, and may potentially imply impaired antitumor effects. Vedolizumab is an anti-integrin α4β7 antibody with gut-specific immunosuppressive effects, approved for Crohn's disease and ulcerative colitis. We report a case series of seven patients with metastatic melanoma or lung cancer, treated with vedolizumab off-label for ipilimumab- or nivolumab-induced enterocolitis, from June 2014 through October 2016. Clinical, laboratory, endoscopic, and histologic data were analyzed. Patients initially received corticosteroids but were steroid-dependent and/or partially refractory. One patient was administered infliximab but was refractory. The median time from onset of enterocolitis to start of vedolizumab therapy was 79 days. Following vedolizumab therapy, all patients but one experienced steroid-free enterocolitis remission, with normalized fecal calprotectin. This was achieved after a median of 56 days from vedolizumab start, without any vedolizumab-related side-effects noted. The patient in whom vedolizumab was not successful, due to active ulcerative colitis, received vedolizumab prophylactically. This is the first case series to suggest that vedolizumab is an effective and well-tolerated therapeutic for steroid-dependent or partially refractory ICPI-induced enterocolitis. A larger prospective study to evaluate vedolizumab in this indication is warranted.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Based on two retrospective series, VDZ is an effective and well-tolerated therapeutic for steroid-dependent or refractory ICI-induced enterocolitis.69,70”
From Autoimmune diseases and immune-checkpoint inhibitors for cancer therapy: Review of the literature and personalized risk-based prevention strategy (2020) · cites this paper as [69]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay‐Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,320
Toxicity and response criteria of the Eastern Cooperative Oncology Group
Oken, M. M., Creech, R. H., Tormey, D. C., Horton, J., Davis, T. E., Mcfadden, E. T., & Carbone, P. P. (1982) · American Journal of Clinical Oncology · doi:10.1097/00000421-198212000-00014 · Cited by 11,686
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
Pembrolizumab versus Ipilimumab in Advanced Melanoma
Robert, C., Schachter, J., Long, G. V., Arance, A., Grob, J. J., Mortier, L., Daud, A., Carlino, M. S., McNeil, C., Lotem, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503093 · Cited by 5,887
Templeton, A. J., McNamara, M. G., Šeruga, B., Vera-Badillo, F., Aneja, P., Ocaña, A., Leibowitz‐Amit, R., Sonpavde, G., Knox, J. J., Tran, B., et al. (2014) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dju124 · Cited by 3,304
Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
Feagan, B. G., Rutgeerts, P. J., Sands, B. E., Hanauer, S. B., Colombel, J., Sandborn, W. J., Assche, G. V., Axler, J. L., Kim, H. J., Danese, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215734 · Cited by 2,892
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
Sandborn, W. J., Feagan, B. G., Rutgeerts, P. J., Hanauer, S. B., Colombel, J., Sands, B. E., Lukáš, M., Fedorak, R. N., Lee, S., Bressler, B. L., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215739 · Cited by 2,716
Bongartz, T., Sutton, A. J., Sweeting, M. J., Buchan, I. E., Matteson, E. L., & Montori, V. M. (2006) · JAMA · doi:10.1001/jama.295.19.2275 · Cited by 2,470
CTLA-4 and PD-1 Pathways: Similarities, Differences, and Implications of Their Inhibition
Buchbinder, E. I., & Desai, A. (2016) · American Journal of Clinical Oncology · doi:10.1097/coc.0000000000000239 · Cited by 2,360
Flagged first, then by citations
Cited by
Sorted by citations
Items 201–235 of 235
Management immunvermittelter Nebenwirkungen
Janning, M., & Loges, S. (2017) · Info Onkologie · doi:10.1007/s15004-017-5562-6
Management immunvermittelter Nebenwirkungen
Janning, M., & Loges, S. (2018) · hautnah dermatologie · doi:10.1007/s15012-018-2606-z
Use of Biologic Drugs Following an Initial Diagnosis of Malignancy
Axelrad, J. E., Chang, S., & Hudesman, D. P. (2019) · Springer eBooks · doi:10.1007/978-3-030-15301-4_12
Managing Checkpoint Inhibitor Symptoms and Toxicity
Pavlick, A. C., & Weber, J. S. (2019) · Springer eBooks · doi:10.1007/978-3-319-46029-1_60-1
Non-Rheumatic Immune-Related Adverse Events
Balaji, A., Shankar, B., & Naidoo, J. (2021) · Springer eBooks · doi:10.1007/978-3-030-56824-5_10
Spectrum and Management of Immune Related Adverse Events Due to Immune Checkpoint Inhibitors
Davies, M. J., & Russo, A. V. (2021) · Current cancer research · doi:10.1007/978-3-030-74028-3_7
Las formas precarias de tenencia y de trabajo de la tierra en la agricultura
Molina, O., & Aurelio, F. (1983) · Repositorio Institucional (Universidad de Cuenca)
(2017) · Reactions Weekly · doi:10.1007/s40278-017-31227-3
Randhawa, M., Gaughran, G., Archer, C., Pavli, P., Morey, A. L., Ali, S. S., & Yip, D. (2019) · World Journal of Clinical Oncology · doi:10.5306/wjco.v10.i10.349
Immunbedingte Toxizitäten behandeln
Rodler, S., Tamalunas, A. J., Schulz, G. B., Apfelbeck, M., Götz, M., Berg, E. K., Stief, C. G., & Casuscelli, J. (2022) · Uro-News · doi:10.1007/s00092-022-5501-1
Yeung, S. J., & Escalante, C. P. (2022) · Holland‐Frei Cancer Medicine · doi:10.1002/9781119000822.hfcm141.pub2
Colitis ulcerosa-assoziiert oder hereditäre Genese?
Lott, S.-J., & Meiborg, M. (2023) · Gastro-News · doi:10.1007/s15036-022-3181-z
Gomez-Escudero, O. (2024) · Revista de Gastroenterología de México · doi:10.1016/j.rgmx.2023.11.001
Onkolojide Moleküler Hedefli Tedaviler
Teker, H. T., Gökoğlu, M., Yılmaz, H. Ö., Yurtsever, İ., Duran, G. G., Işık, U., Tacar, S. Y., Demir, N., Yıldız, H. İ., Aslan, F., et al. (2022) · Akademisyen Kitabevi eBooks · doi:10.37609/akya.1478
Wang, L., Zhang, S.-M., & Chen, X.-Q. (2024) · World Journal of Gastrointestinal Surgery · doi:10.4240/wjgs.v17.i1.99122
Immunotherapy for Breast Cancer Survivors: Implications for Clinical Practice
Özkan, M. (2024) · Springer eBooks · doi:10.1007/978-3-031-75480-7_6
Rizvi, S. S., Gianarakis, M., Pueringer, J., Méndez, G., Garrad, E. C., Chuy, V., Chandran, S., Holscher, C., & Ali, S. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-24742-2.00018-6
Shatila, M., & Wang, Y. (2025) · Gastrointestinal Endoscopy · doi:10.1016/j.gie.2024.11.008
Adverse reactions of immune checkpoint inhibitors
Рафилевна, З. Э., Kaliberdenko, V. B., Рустамовна, К. Э., Beter, V. S., Pronkina, T. V., Kushner, V. A., & Taran, V. V. (2025) · Medical Immunology (Russia) · doi:10.15789/1563-0625-aro-3191
Zhang, Q., Meng, F., Cao, Y., Zhu, X., Zhang, Y., & Xiao, Y. (2025) · Case Reports in Hematology · doi:10.1155/crh/9967011
Gastrointestinal complications of immune checkpoint Inhibitor therapy
Carbonnel, F., Martin, A., Marthey, L., Bellanger, C., Bou-Farah, R., Boytchev, I., Abdallah, R., Amiot, A., & Meyer, A. (2025) · La Presse Médicale · doi:10.1016/j.lpm.2025.104326
Additional file 2 of The role of T cell trafficking in CTLA-4 blockade-induced gut immunopathology
Zhang, S., Liang, W., Luo, L., Sun, S., & Wang, F. (2020) · Figshare · doi:10.6084/m9.figshare.11998896
Additional file 3 of The role of T cell trafficking in CTLA-4 blockade-induced gut immunopathology
Zhang, S., Liang, W., Luo, L., Sun, S., & Wang, F. (2020) · Figshare · doi:10.6084/m9.figshare.11998902
Additional file 5 of The role of T cell trafficking in CTLA-4 blockade-induced gut immunopathology
Zhang, S., Liang, W., Luo, L., Sun, S., & Wang, F. (2020) · Figshare · doi:10.6084/m9.figshare.11998914
Additional file 1 of The role of T cell trafficking in CTLA-4 blockade-induced gut immunopathology
Zhang, S., Liang, W., Luo, L., Sun, S., & Wang, F. (2020) · Figshare · doi:10.6084/m9.figshare.11998887
Additional file 4 of The role of T cell trafficking in CTLA-4 blockade-induced gut immunopathology
Zhang, S., Liang, W., Luo, L., Sun, S., & Wang, F. (2020) · Figshare · doi:10.6084/m9.figshare.11998911
Fidelle, M. (2021) · theses.fr (ABES) · doi:10.70675/2168c5d5zc7cez4351zb678z1a8c9761484f
Moura, M. J., Chatterjee, A., Wali, S., Garza, D. M., Salim, H., Rong, J., Menon, R., Jafri, F. I., Rivera, A. C. U., Mortan, R. E., et al. (2026) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2026.2659253
Mierzejewska, M., Akily, L., Karlsen, W., Teodorczyk, J., Tomasik, B., Rutkowski, J., Wiśniewski, P., Śledziński, M., Markiet, K., Szade, J., et al. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1780838
Ma, S., Rong, J., Wu, X., Wu, X., Gao, Y., Li, H., & Yan, T. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1852152
Advanced Therapies for the Management of Immune Checkpoint Inhibitor-Induced Colitis
Matichecchia, C. S., Fanizzi, F., Zilli, A., Ferrara, R., Oresti, S., Albarello, L., Allocca, M., Peyrin‐Biroulet, L., Danese, S., & D’Amico, F. (2026) · Cancers · doi:10.3390/cancers18193108
Wasim, M., Ma, G., & Wang, Y. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1914702
Shi, C., Li, C., & Yan, J. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1958441
Parkes, J., & Moreira, F. (2026) · Advances in computational intelligence and robotics book series · doi:10.4018/979-8-3373-6551-0.ch014
Metadata
- Authors
- Bergqvist, V., Hertervig, E., Gedeon, P., Kopljar, M., Griph, H., Kinhult, S., Carneiro, A., & Marsal, J.
- Affiliations
- Skåne University Hospital (SE)
- Lund University (SE)
- Corresponding author
- Marsal, Jan
- Venue
- Cancer Immunology Immunotherapy
- Published
- 2017-02-15
- Volume
- 66
- Issue
- 5
- Pages
- 581-592
- ISSN
- 0340-7004 (ISSN-L)
- 1432-0851
- PMC
- PMC5406433
- OpenAlex
- W2588366403
- Cited by
- 234
- References
- 56
- Citations by year
- 2026: 10 · 2025: 14 · 2024: 20 · 2023: 13 · 2022: 24 · 2021: 33 · 2020: 41 · 2019: 37 · 2018: 35 · 2017: 6
- FWCI
- 14.35
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Locations
- Cancer Immunology Immunotherapy (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Lund University Publications (Lund University) (submittedVersion)
- Funders
- Hedlund Foundation
- Alfred Österlunds Stiftelse
- Julin Foundation
- Kungliga Fysiografiska Sällskapet i Lund
- Svenska Läkaresällskapet
- Grants to researchers in the public health care from the Swedish government (ALFSKANE-539811)
- Healthcare Region of Southern Sweden
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Gastroenterology › Inflammatory Bowel Disease
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
- Keywords
- vedolizumab, immune-related adverse events, ipilimumab, nivolumab, pembrolizumab, CTLA-4, PD-1, metastatic melanoma, lung cancer, off-label drug use, fecal calprotectin, ulcerative colitis
- MeSH terms
- Ipilimumab, Nivolumab, Adult, Aged, Antibodies, Monoclonal, Carcinoma, Non-Small-Cell Lung, Enterocolitis, Female, Gastrointestinal Agents, Humans, Lung Neoplasms, Male, Melanoma, Middle Aged, Cell Cycle Checkpoints, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
